Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven A. Ledger
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Beta
- 0.03
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.52
Financials
Revenue
$0.00-100.0%Net Income
$-6.36MEBITDA
$-7.42MFree Cash Flow
$-6.68MEPS (diluted)
$-0.55Shares Outstanding (diluted)
16.39M+1508.3%Operating Expenses
$6.78MCash & Debt
$23.02MReturn of Capital
$2.54MRevenue by Segment (annual)
$130.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-19.18M | $-1.91 |
| 2024 | $56.0K | $-11.14M | $-1.51 |
| 2023 | $3.15M | $5.27M | $0.63 |
| 2022 | $500.0K | $-2.68M | $-2.49 |
| 2021 | $3.46M | $-1.26M | $-0.59 |
| 2020 | $54.0K | $-10.87M | $-10.14 |
| 2019 | $1.73M | $-12.15M | $-11.47 |
| 2018 | $1.40M | $-7.50M | $-7.56 |
| 2017 | $1.40M | $-6.58M | $-6.46 |
| 2016 | $1.67M | $-15.49M | $-15.21 |
Valuation
SERhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-29.41%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·12d ago·Negative
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress" Featuring Serina Therapeutics' CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson's disease with no major clinical advances in 50+ years Meet with Serina's CEO Steven Ledger Register at AdvancingParkinsonsDisease.TribePublic.com HUNTSVILLE, AL, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Se…
View source ↗ - Newsglobenewswire.com·27d ago·Negative
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2 - Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were consistent with the sustained apomorphine exposure SER-252 is designed to provide – - Blinded Cohort 1 observations included sustained periods of im…
View source ↗ - Newsglobenewswire.com·53d ago·Negative
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the second quarter ended June 30, 2026, along with key business updates.
View source ↗
Earnings
Wed, Nov 18(in 6 weeks)
Consensus estimate $-0.34 per share
Typical surprise -17.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.55 vs $-0.47miss
- Thu, May 14$-0.58 vs $-0.44miss
- Mon, Mar 23$-0.31 vs $-0.50beat
- Thu, Nov 13$-0.45 vs $-0.47beat
- Mon, Aug 11$-0.66 vs $-0.36miss
- Thu, May 8$-0.49 vs $-0.62beat
Estimates and results for SER via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SER officers and directors.
- Bought
- $78k
- Sold
- $386k
7 trades
23 trades
- Brannan Stephen K.bought
- Wilson Karen Jbought
- Wilson Karen Jbought
- Venkatesan Jaybought
- Wilson Karen Jbought
- Wilson Karen Jbought
- Marshall Richard Peterbought
- Moreadith Randallsold
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SER.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.